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Abstract
Background: Stereotactic body radiation therapy (SBRT) is an emerging option for 
unresectable hepatocellular carcinoma (HCC) without consensus regarding optimal 
dose schemas. This analysis identifies practice patterns and factors that influence 
dose selection and overall survival, with particular emphasis on dose and tumor size.
Materials/Methods: Query of the National Cancer Database (NCDB) identified pa-
tients with unresectable, nonmetastatic HCC who received SBRT from 2004 to 2013. 
Biological Effective Dose (BED) was calculated for each patient in order to uni-
formly analyze different fractionation regimens.
Results: A total of 456 patients met the inclusion criteria. The median BED was 
100 Gy (22.5‐208.0), which corresponded to the most common dose fractionation 
(50 Gy in five fractions). Various factors influenced dose selection including tumor 
size (P < 0.001), tumor stage (P = 0.002), and facility case volume (<0.001). On 
multivariate analysis, low BED (<75 Gy, HR 2.537, P < 0.001; 75‐100 Gy, HR 
1.986, P = 0.007), increasing tumor size (HR 1.067, P = 0.032), elevated AFP (HR 
1.585, P = 0.019), stage 3 (HR 1.962, P < 0.001), low‐volume facilities (1‐5 cases 
HR 1.687, P = 0.006), and a longer time interval from diagnosis to SBRT (>2 to 
≤4 months, HR 1.456, P = 0.048; >4 months, HR 2.192, P < 0.001) were associated 
with worse survival.
Conclusion: SBRT use is increasing for HCC, and multiple regimens are clinically 
employed. Although high BED was associated with improved outcomes, multiple 
factors contributed to the dose selection with favorable patients receiving higher 
doses. Continued efforts to enhance radiation planning and delivery may help im-
prove utilization, safety, and efficacy.
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1 |  INTRODUCTION
Hepatocellular carcinoma (HCC) is a primary liver malig-
nancy often arising from etiologies that cause chronic inflam-
mation and cirrhosis. Its relatively poor prognosis is reflected 
by its rank as third in cancer mortality worldwide.1 HCC is a 
growing problem with tripling incidence in the United States 
since 1980.2 Various options are available for treatment, with 
transplantation or partial hepatectomy being the standard of 
care. Unfortunately, less than 30% of people are candidates 
for surgical therapies due to disease extent, location of tumor, 
and other medical comorbidities.2,3 For the majority with in-
operable HCC, therapeutic options include radiofrequency 
ablation (RFA), percutaneous ethanol injection, and arterial 
embolization treatments: bland, conventional chemoemboli-
zation, or radioembolization. These modalities can be limited 
by various factors including invisibility of tumor on ultra-
sound, coagulopathy, tumor size, and proximity to structures 
such as the gallbladder, hepatic hilum, or vasculature.4
Radiation therapy has not traditionally been considered as 
a viable option for the treatment of HCC due to the sensitivity 
of the liver to radiation; however, advances in radiation tech-
nique (3D‐conformal, intensity‐modulated radiation therapy) 
and delivery (respiratory motion management, image guid-
ance) have resulted in the development of stereotactic body 
radiation therapy (SBRT).5 SBRT delivers high‐dose ablative 
radiation to precisely delineated targets with tight conformity 
and a steep dose falloff in a limited number of treatment ses-
sions. The sparing of the normal liver and other surround-
ing structures from high doses while delivering significant 
dose to the tumor results in a safe and effective therapy with 
limited toxicity. As this technique has evolved, several small 
prospective studies and single institutional reviews have been 
published.6-16 These results show promise in terms of local 
control and overall survival, especially considering the lim-
ited treatment options available for most of the patients re-
ceiving SBRT.
Despite the success and increased application of SBRT 
techniques for treating unresectable HCC, there remain im-
portant questions about the optimal radiation schema, patient 
selection, and factors predictive of survival outcome. To help 
address these questions, we have used the National Cancer 
Database (NCDB) to analyze the largest cohort of HCC pa-
tients receiving SBRT therapy.
2 |  METHODS
This Institutional Review Board (IRB)‐approved study 
surveyed the National Cancer Database (NCDB) to iden-
tify HCC patients through utilization of the International 
Classification of Diseases‐Third revision (ICD‐3) histology 
codes, 8170‐8175 (HCC) combined with site‐specific code, 
C22.0 (liver). This database, a result of a joint program be-
tween the American College of Surgeon (ACS)‐Commission 
on Cancer (COC) and the American Cancer Society, captures 
a wide variety of clinicopathologic characteristics from reg-
istries of more than 1500 CoC‐accredited hospitals in the 
United States and includes approximately 65% of all new 
liver malignancies.
The final cohort included patients with nonmetastatic 
HCC, defined as, stage I/II/III disease according to the 
American Joint Committee on Cancer (AJCC) staging 
system (7th edition), who received SBRT, as defined by 
delivery of ≤five fractions of radiation with fractional 
doses higher than standard palliative regimens consistent 
with current practices and trends due to insurance reim-
bursement in the United States. The clinicopathologic 
variables extracted included patient demographics, Alpha‐
Fetoprotein level (AFP), Charlson Comorbidity Index 
(CCI), tumor size, disease stage, radiation dose, and num-
ber of treatments. Biological Effective Dose (BED) was 
calculated with the following formula17:
With n = number of treatment, d = dose per fraction, and 
α/β ratio of 10 for each case to account for the various frac-
tionation schemes that was used.
Facility case volume was calculated by counting the num-
ber of cases associated with each facility ID over the study 
period and classified as high (>20 cases), moderate (6‐20 
cases), and low (five or fewer cases). The NCDB records the 
receipt of chemotherapy, but does not give detailed informa-
tion about the specific types or delivery methods, so some 
patients coded as receiving chemotherapy may have actually 
received transarterial chemoembolization (TACE), which is 
more common in this population.
Descriptive analysis of the frequency of different frac-
tionation schemas, BED frequencies, and associations with 
tumor size and survival were performed. Univariate com-
parisons were made using chi‐square, ANOVA, and/or t 
tests. While all 456 patient data sets were used to charac-
terize the cohort, only the 355 patients with follow‐up and 
status at last known contact were included in the survival 
analysis. Kaplan‐Meier curves and log‐rank tests were used 
to examine survival outcomes, while multivariate Cox pro-
portional hazards model was used to identify predictors of 
survival. Overall Survival (OS) was calculated from the 
time of SBRT until the time of death. Hazards ratio (HR) 
and 95% confidence intervals (CI) were reported for the 
Cox regression analysis. Alpha was established at 0.05 for 
all tests and P < 0.05 was considered significant. Statistical 
analyses were performed using SPSS version 24.0 (IBM 
Corp, New York, NY).
BED=nd
[
1+
d
훼∕훽
]
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3 |  RESULTS
A total of 456 patients were found to have received liver 
SBRT for HCC. The median patient age and tumor size were 
62 years (27‐90) and 3.2 cm (0.6‐17), respectively. Table 1 
shows patient demographics for the whole group as well 
as divided into groups by BED dose. Most cases were pri-
mary lesions, but 21 patient (<5%) had surgical procedure 
T A B L E  1  Characteristics of HCC patients receiving SBRT from the NCDB (2004‐2013)
Variables (n)
Total cohort 
(n = 456)
Division by BED (Gy)
<75 (n = 141) ≥75 to ≤100 (n = 126) >100 (n = 133) P‐value
Age (y), median 
(range)
63 (57‐74) 64 (27‐89) 61 (48‐85) 66 (36‐90) 0.880
≥65 y 209 (45.3%) 65 (46%) 50 (40%) 59 (44%) 0.556
Gender Male 340 (73.7%) 103 (73%) 95 (75%) 94 (71%) 0.694
Ethnicity
Caucasian 372 (80.7%) 117 (83%) 102 (81%) 108 (81%) 0.927
African American 51 (11.1%) 13 (9%) 13 (10%) 16 (12%)
Others 38 (8.2%) 11 (8%) 11 (9%) 9 (7%)
Insurance
Not insured 16 (3.5%) 3 (2%) 6 (5%) 3 (2%) 0.663
Private 145 (31.5%) 43 (30%) 39 (31%) 45 (34%)
Government 298 (64.6%) 94 (67%) 81 (64%) 85 (64%)
Unknown 2 (0.4%) 1 (0.7%) 0 (0%) 0 (0%)
Charlson‐Deyo Score
0 281 (61.0%) 89 (63%) 68 (54%) 82 (62%) 0.135
1 91 (19.7%) 28 (20%) 34 (27%) 20 (15%)
≥2 89 (19.3%) 24 (17%) 24 (19%) 31 (23%)
AFP level
Normal 130 (28.2%) 39 (28%) 37 (29%) 47 (35%) 0.626
Elevated 244 (52.9%) 79 (56%) 65 (52%) 64 (48%)
Unknown 87 (18.9%) 23 (16%) 24 (19%) 22 (17%)
Stage
Stage I 257 (55.7%) 64 (45%) 74 (59%) 84 (63%) 0.002
Stage II 134 (29.1%) 44 (31%) 39 (31%) 37 (28%)
Stage III 70 (15.2%) 33 (23%) 13 (10%) 12 (9%)
Median tumor size 
(cm)
3.2 cm (0.6‐17.0%) 4.5 cm (1.1‐17.0) 3.0 cm (1.0‐10.8) 2.7 cm (1.0‐14.0) <0.001
Chemotherapy
None 303 (66.4%) 110 (78%) 64 (51%) 89 (67%) <0.001
Yes 147 (32.2%) 29 (20%) 62 (48%) 39 (29%)
Unknown 6 (1.3%) 2 (1%) 0 (0%) 5 (4%)
Treating facility
Academic 337 (73.9%) 104 (74%) 102 (81%) 100 (75%) 0.385
CCC 88 (19.3%) 25 (18%) 17 (14%) 27 (20%)
Other 31 (6.8%) 12 (9%) 7 (6%) 6 (5%)
Facility case volume
>20 187 (41.0%) 47 (33.3%) 69 (54.8%) 61 (45.9%) <0.001
6‐20 87 (19.1%) 46 (32.6%) 19 (15.1%) 19 (14.3%)
1‐5 182 (29.9%) 48 (34.0%) 38 (30.2%) 53 (39.8%)
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prior to SBRT (partial liver resection in 10 patients and 
ablation in 11 patients; median time from procedure to 
SBRT of 93 days) and 132 patients (29%) received some 
form of chemotherapy prior to SBRT (median time from 
chemotherapy to SBRT was 73 day). Patients with prior 
therapy had a longer time from diagnosis to SBRT (prior 
surgery: median time of 151 days vs 80 days for no prior 
surgery P = 0.02951; prior chemotherapy: median 131 days 
vs 72 days for no prior chemotherapy P < 0.001). During 
the study period from 2004 to 2013, the use of SBRT for 
liver HCC increased dramatically from four cases in 2004 
to 100 cases in 2013. Figure 1 shows the use of SBRT over 
the study period, the distribution of each dose‐fractionation 
schema, and the distribution of BED.
The majority of the treatments in this US‐based cohort 
were delivered with 5‐fraction regimens (55% 5‐fraction, 
39.5% 3‐fraction, and 3.9% 4‐fraction). The median BED was 
100 Gy (22.5‐208.0), which corresponded to the most com-
mon dose fractionation (50 Gy in 5 fractions) in 23.0%. Other 
common schemes included 40 Gy in five fractions (BED of 
72 Gy) in 15.3%, 48 Gy in three fractions (BED of 124 Gy) 
in 11.5%, 45 Gy in three fractions (BED of 112.5 Gy) in 
6.8%, and 54 Gy in three fractions (BED of 151 Gy) in 4.3%. 
In comparison to commonly used regimens, patients who re-
ceived 48 Gy in three fractions had a shorter time interval to 
SBRT, treatment at high‐volume academic facilities, received 
less chemotherapy, and had better outcomes than patients re-
ceiving other common regimens (Table 2). Patients treated 
with three fraction regimens tended to receive higher BED, 
receive treatment at nonacademic facility, and have a shorter 
time from diagnosis to SBRT. Various factors contributed to 
the selection of SBRT doses including stage, tumor size, fa-
cility case volume, and the use of chemotherapy.
After a median follow‐up was 16 months, a total of 217 
(60.9%) patients had died. Patients alive at last encounter had 
a median follow‐up of 31 months compared to the 16 months 
for patients who died. The median OS after SBRT for the en-
tire cohort was 20.3 months. Long‐term survival was observed 
with 75% of those surviving longer than 3 years alive at last 
follow‐up (range 36.2 to 91.4 months, median 54.25 months). 
Increasing BED was associated with improved survival. 
The median and 1‐year OS were 15.3 months and 56.6% for 
F I G U R E  1  A, Incidence of SBRT use from 2004 to 2013; B, Use of common fractionation regimens over the study period; C, Distribution of 
SBRT dose regimens; D, Distribution of BED
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BED ≤ 75, 18.3 months and 67.5% for BED > 75 and ≤100, 
and 37.2 months and 81.4% for BED > 100, P < 0.001. 
Increasing tumor size also correlated with worse outcome. The 
median and 1‐year OS were 46.5 months and 81.3% for size 
≤2 cm, 19.5 months and 70.6 for size >2 cm and ≤4 cm, and 
15.1 months and 58.5% for size >4 cm, P < 0.001 (Figure 2). 
BED greater than 100 Gy did not benefit all tumor sizes 
equally. For tumors greater than 4 cm, there was no improve-
ment with BED greater than 100 Gy, but for tumors ≤4 cm, 
there was an improvement in overall survival (Figure 2).
On multivariate analysis, low BED, elevated AFP, larger 
tumor size, increased interval from diagnosis to SBRT, and 
low facility SBRT volume were associated with worse sur-
vival (Table 3). There was an inverse relationship between 
the size of the tumor and the BED in relation to survival. 
For patients surviving less than 1 year, more than 1 year to 
3 years, and more than 3 years, the median tumor size de-
creased from 3.75 cm to 3.0 cm to 2.7 cm (P < 0.001), 
while the median BED increased from 92.75 Gy to 100 Gy 
to 112.5 Gy (P < 0.001), respectively. Correlation between 
tumor size, BED, and survival is shown in Figure 3.
4 |  DISCUSSION
Due to improvements in technology and an enriched under-
standing of the liver's tolerance of radiation, stereotactic ra-
diation body radiation therapy has emerged as a promising 
treatment for unresectable HCC. There is growing accept-
ance and application of this technique for managing HCC 
as shown by the dramatic rise in its use over the study pe-
riod. Despite the growing availability of liver SBRT, there 
remains little consensus about the best treatment regimen.18 
This study confirms the wide variation of regimens used in 
clinical practice and identifies 50 Gy in five fractions as the 
most common scheme in this cohort of patients treated in the 
United States, which is also the recommended dose on the 
currently enrolling RTOG 1112 protocol, if liver constraints 
can be achieved. The variation in treatment regimens reflects 
the multiple factors that are considered in determining the 
dose including the size and location of the lesion, the radia-
tion tolerance of nearby organs, liver health, the amount of 
liver spared from significant radiation doses, institutional 
preference, and organ motion managment.5,18,19
Given the variation in doses and fractionation schemes 
used, all of the doses were converted to Biological Effective 
Dose (BED) in order to accommodate direct comparisons be-
tween different regimens17 and evaluate the impact of dose 
and outcome. Correlation between dose, tumor size, and 
overall survival emerged, which is partially explained by the 
aforementioned factors as patients with the most favorable 
factors likely were given higher BED prescriptions. In this 
cohort, those receiving high BED treatments tended to have TA
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smaller tumors, normal AFP, and earlier tumor stage than 
those who received low BED treatments. Other studies have 
also reported an inverse relationship between the size of the 
tumor and the prescription dose for SBRT.6,20,21 The specific 
dose‐fractionation scheme may be less important than safely 
treating to the appropriate BED for each patient's clinical 
situation.
It has been over 20 years, since the first clinical expe-
rience with SBRT for HCC showed efficacy.22 This was 
followed by multiple retrospective and prospective reports 
further supporting and validating SBRT as a promising 
option for HCC.6-12,15 Table 4 summarizes select stud-
ies. Among the published studies, overall survival varies 
considerably based on the cohort composition. The cur-
rent study is the largest evaluating overall survival and 
practice patterns from a diverse group. Based on BED, it 
reports similar survival outcomes compared to other pub-
lished reports (55% 1‐year OS for Bujold et al with median 
BED of 54 Gy vs 56.6% 1‐year OS for patients with BED 
<75 Gy from current study and 61%‐67% 3‐year OS re-
ported by Kang et al and Lasley et al with median BED 
of 124‐165 Gy vs 50.6% 3‐yr survival for BED >100 Gy 
in the current study). Although some variation is expected 
given the increased cohort heterogeneity and decreased 
selectivity compared to prospective trials, it appears the 
outcomes seen with SBRT in practice are reasonably com-
parable to previous reports.
The current study suggests that elevated AFP, larger tumor 
size, stage 3 disease, low facility case volume, increased time 
interval from diagnosis to receiving SBRT, and low BED 
are associated with poor survival for unresectable HCC pa-
tients treated with SBRT. While several of these factors have 
been identified as prognostic factors in other studies (elevated 
AFP,9,23 tumor size,11,21,23,24 SBRT dose,8,10,11,25 advanced 
stage6,26), low facility case volume and increased time interval 
from diagnosis to receiving SBRT are new and may warrant 
further study. Since liver SBRT is a relatively new technique, 
facility volume and provider experience may influence results 
similar to that of surgical outcomes for complicated oncologic 
cancers27,28 or when intensity‐modulated radiation therapy 
was first introduced for head and neck cancer treatment.29 Each 
of these situations requires mastering complicated procedures, 
understanding complex anatomy, and managing multiple 
prognostic variables similar to that needed for liver SBRT. It 
could also reflect better practices for preventing liver toxicity 
or advanced technology in place at busier centers that could 
improve SBRT efficacy and safety such as advanced image 
guidance, established respiratory motion strategies, and MRI 
simulation. To this point, the Princess Margaret experience 
showed improved outcomes in patients treated on their second 
trial, which they attributed to better patient selection, diag-
nostic imaging, target identification, and radiation planning/
delivery.6 Additionally, the University of Michigan group re-
ported no local failures using fiducials to enhance image guid-
ance compared to 10% failure rate without fiducials, which 
further highlights the importance of image guidance and the 
technical components of SBRT treatment. These factors are 
developed and enhanced with expertise and experience from 
F I G U R E  2  Kaplan Meier curves for overall survival: A, Commonly used regimens; B, BED; C, Size; D, Tumors <2 cm; E, Tumors 2 cm to 
<4 cm; F, Tumors ≥4 cm
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larger case volumes. A longer time interval from diagnosis to 
SBRT may be associated with a worse outcome due to tumor 
growth and invasion leading to more advanced tumors at the 
time of SBRT, worsening liver function over time, or could 
reflect failed initial treatments, which could make SBRT more 
complicated and less efficacious. In the current study, patients 
with prior therapy had a longer time from diagnosis to SBRT 
than those without prior therapy.
Multiple groups have evaluated the impact of SBRT dose 
on outcomes with several reporting improved local control 
with increased dose.8,10,11,25 Scorsetti et al10 reported 100% 
local control for tumors that received a BED dose of 
>100 Gy vs 52% for those with <100 Gy BED. Likewise 
Kang et al8 reported improved 2‐year local control (100% 
vs 87%) and progression‐free survival (52.5% vs 17.3%) for 
BED ≥151 Gy vs <151 Gy. Additionally, Jang et al25 re-
ported not only improved local control, but also improved 
overall survival for patients receiving a BED ≥151 Gy 
compared to lesser dose regimens. To the contrary, several 
groups found no relationship between dose and outcome. In 
T A B L E  3  Univariate and multivariate analysis for overall survival
Category
Univariate analysis Multivariate analysis
Hazard ratio
95% Confidence 
interval P‐value Hazard ratio
95% Confidence 
interval P‐value
Age continuous 
variable
1.009 0.997‐1.021 0.153    
Sex (male (ref) vs 
female)
0.998 0.740‐1.346 0.99    
Charlson‐Deyo Score
0 (ref) (ref) (ref)
1 1.086 0.752‐1.568 0.661
2 1.144 0.736‐1.777 0.55
AFP Normal (ref) (ref) (ref) (ref) (ref) (ref) (ref)
AFP Elevated 1.617 1.145‐2.284 0.006 1.585 1.078‐2.329 0.019
AFP unknown 1.996 1.335‐2.983 0.001 1.865 1.160‐2.999 0.010
Tumor size (cm) 
(continuous)
1.119 1.072‐1.169 <0.001 1.067 1.006‐1.131 0.032
Stage
1 (ref) (ref) (ref) (ref) (ref) (ref)
2 1.326 0.974‐1.805 0.073 1.326 0.974‐1.805 0.073
3 1.962 1.384‐2.780 <0.001 1.962 1.384‐2.780 <0.001
Treating facility
Academic (ref) (ref) (ref)
CCC 1.188 0.644‐2.191 0.581 NS NS NS
Other 1.942 1.013‐3.725 0.046
Facility case volume
>20 (ref) (ref) (ref) (ref) (ref) (ref)
6‐20 1.814 1.341‐2.454 <0.001 1.324 0.862‐2.003 0.200
1‐5 2.101 1.453‐3.038 <0.001 1.687 1.165‐2.442 0.006
Months from diagnosis to SBRT
≤2 mo (ref) (ref) (ref) (ref) (ref) (ref)
>2 mo to  ≤4 mo 1.468 1.055‐2.043 0.023 1.456 1.004‐2.113 0.048
>4 mo 1.422 0.955‐2.031 0.053 1.586 1.069‐2.353 0.022
BED
>100 Gy (ref) (ref) (ref) (ref) (ref) (ref)
≥75 Gy and ≤100 Gy 1.986 1.371‐2.875 <0.001 1.698 1.158‐2.490 0.007
<75 Gy 2.537 1.767‐3.643 <0.001 2.192 1.485‐3.235 <0.001
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series of small tumors with the majority receiving high‐dose 
treatments, neither Su et al nor Wahl et al reported a differ-
ence in outcome‐related SBRT dose.13,15 They speculated 
that their delivered dose even in the lower dose patients was 
sufficiently high to achieve local control.13 In the Princess 
Margaret cohort of large advanced tumors, no difference in 
local control was observed with increased SBRT dose, but 
most tumors were treated with relatively low BED due to 
the risk of liver failure (median BED was 57.6 Gy).6 The 
current study shows improved outcomes with increasing 
BED dose, particularly in those who received a >100 Gy 
BED, but the benefit of high dose was less significant in pa-
tients with larger tumors. This could be due to the inability 
to achieve a high dose in these larger tumors while respect-
ing normal liver constraints, or possibly, from liver related 
toxicity in those with large tumors inappropriately treated 
with high doses. There are many challenges in evaluating 
the role of dose from previous reports including: homoge-
neous patient populations, only minor differences in eval-
uated SBRT dose regimens, and small sample sizes. The 
current study adds to the discussion about dose, because 
it includes a large patient population with a broad range of 
SBRT doses and practice patterns. Patient selection likely 
contributed significantly to the overall survival benefit that 
was observed. The positive impact of dose on outcomes for 
unresectable HCC is also supported by several older studies 
with more traditional extended fractionation.30-32 Likely, 
the true value of escalated dose depends on multiple fac-
tors, particularly whether it can be done safely.5,33 Efforts 
to use modern radiation techniques or even newer therapies 
like proton beam radiation to stay within organ constraints 
and apply recommendations from predictive models to indi-
vidually access the risk of liver toxicity with different doses 
are warranted.5,33
Several significant limitations of this study relate to 
its retrospective nature and the available information in 
the database. The NCDB database does not include infor-
mation about tumor location, tumor number, Child Pugh 
status, treatment related toxicity, local control, or cause 
of death, which are key factors related to liver SBRT. Of 
these the most critical is the lack of information related 
to liver function, as this is a key determinant in deciding 
what dose to use and if SBRT is a safe option for the pa-
tient. Using too high of a BED scheme in a patient with 
poor liver function can result is severe toxicity and even 
death.34 Additionally, some elements of the radiation treat-
ment are not reported in the database such as the isod-
ose coverage, maximal/minimal dose, margin expansion, 
or dose to the organs‐at‐risk most importantly the liver. 
As such these results should be considered as exploratory 
in nature and not evidence to systematically apply higher 
BED regimens in all cases. Despite these limitations, this 
study provides insight into current practice patterns and 
suggests some relationships that may be useful for im-
proving outcomes, and understanding the role of SBRT 
for unresectable HCC. The development of techniques 
and strategies to safely deliver high BED regimens may 
further enhance treatment, while limiting the risk of po-
tential acute side effects and late toxicities. Further study 
may better elucidate a specific dose threshold for excellent 
tumor control and low toxicity.
In summary, SBRT is an effective option for unresectable 
HCC and is growing in its use and application in clinical 
practice. Multiple fractionation schemas are used and sev-
eral factors including tumor size, stage, and facility volume 
likely play a role in the selection process. Higher BED treat-
ments may help improve outcomes in properly selected pa-
tients, but care must be taken to ensure it can be done without 
F I G U R E  3  Relationships between BED, tumor size, and survival. A, Heat map showing the frequency of BED and tumor size; B, Scatter plot 
and frequency curves of BED and tumor size divided into survival groups (<1 y, 1 to <3 y, and ≥3 y)
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T A B L E  4  Selected studies of stereotactic body radiation therapy for HCC
Study
Median 
follow‐
up (m)
# of 
patients Median dose/BED
Median tumor 
size Local control
Overall 
survival Toxicity Comments
Bujold6 31 (2‐36) 102 36 Gy in 6 fx (24‐54) 117 cc/7.2 cm 1‐y 97% Median 17 m 30% Grade 
≥3
55% with PVT
BED: 57.6 Gy 
(33.6‐102.6)
1‐y 55% 61% with 
multiple 
lesions
Lasley7 CPA: 33 59 CPA: 48 Gy 
(36‐48 Gy/3 fx)
34 cc 1 year Median/3‐
year
Grade≥3 20% with PVT
CPB: 46 CPA: 39 BED: 124 Gy 
(79.2‐124)
CPA: 91% CPA: 
44.8 m/61%
CPA: 11%
CPB: 21 CPB: 82% CPB: 
17.0 m/26%
CPB: 38%
CPB: 40 Gy/5 fx
BED: 72 Gy
Kang8 17 m 
(6‐38)
47 57 Gy in 3 fx 
(42‐60 Gy in 3 fx)
14.9 cc/2.9 cm 2 y 95% 2‐y 69% 6.4% 
Grade ≥3
100% had 
prior TACE 
procedureBED: 165.3 Gy 
(100.8‐180)
Takeda9 41 90 40 Gy in 5 fx (35‐40 
in 5 fx)
2.3 cm 3 y 96.3% Median 
54.7 m
Total Gr 3 
toxicity 
of 16.7%,
42% recur-
rences after 
other prior 
therapiesBED: 59.5‐72 Gy 3‐y 66.7% No Gr 4‐5
Scorsetti10 8 43 <3 cm: 48‐75 Gy in 
3 fx
4.8 cm 1‐y Median/1‐y 16% Grade 
≥3
47% CPB, 
20% PVT
BED: 
124.8‐262.5 Gy
All patients: 
86%
18 mo/78%
BED>100: 
100%
3‐6 cm: 36‐60 Gy in 
6 fx
BED<100: 
52%
BED: 57.6‐120 Gy
Bibault11 10 75 45 Gy in 3 fx 
(24‐45 Gy in 3 fx)
3.7 cm 1 y 89% 1‐y 78.5% Gr 3 in 8% 51% prior 
other tx, CPB 
12%,BED: 112.5 Gy 
(43.4‐112.5 Gy)
Gr 4 in 1%
Sanuki12 24 185 40 Gy in 5 for CPA, 
BED 72 Gy
7.2 cc 3‐y 91.6% 3‐y 72.1% 1.5% 
Grade 3
~70% had 
prior liver 
treatment, 
15% CPB, 
84% stage I
35 Gy in 5 for CPB, 
BED 59.5 Gy
8.9 cc 3 y 90.7% 3‐y 66.0% 8.3% 
Grade 3, 
grade 5 
in 7% of 
CPB
Su15 21 132 42‐46 Gy in 3‐5 
fractions
3 cm 1 y 90% 3‐y 73.5% Gr ≥3 of 
8.3%
CPB in 14%,
BED: 78‐115 Gy
Current 
Study
16 362 23%‐50 Gy in 5, 
BED 100
3.2 cm NA Median 20 m NA 12% stage 3, 
>50% with 
elevated AFP15.3%‐40 Gy in 5, 
BED 72
1‐y 69.7%
11.5%‐48 Gy in 3, 
BED 124
3‐y 36%
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significantly increasing the risk of toxicity. Additional study 
on factors affecting SBRT outcome and the role of SBRT in 
treating HCC is warranted.
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